Figure 2From: A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [11C]erlotinib and [18F]afatinib in lung cancer-bearing mice Immunohistochemical staining of NSCLC xenograft lines as used in PET studies. Images depicted at 5× magnification. Mutations: A549 (wild type), H1975 (L858R/T790M), and HCC827 (exon 19 deletion).Back to article page